TY - JOUR
T1 - Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
AU - Di Nicolantonio, Federica
AU - Arena, Sabrina
AU - Tabernero, Josep
AU - Grosso, Stefano
AU - Molinari, Francesca
AU - Macarulla, Teresa
AU - Russo, Mariangela
AU - Cancelliere, Carlotta
AU - Zecchin, Davide
AU - Mazzucchelli, Luca
AU - Sasazuki, Takehiko
AU - Shirasawa, Senji
AU - Geuna, Massimo
AU - Frattini, Milo
AU - Baselga, José
AU - Gallicchio, Margherita
AU - Biffo, Stefano
AU - Bardelli, Alberto
PY - 2010/8/2
Y1 - 2010/8/2
N2 - Personalized cancer medicine is based on the concept that targeted therapies are effective on subsets of patients whose tumors carry specific molecular alterations. Several mammalian target of rapamycin (mTOR) inhibitors are in preclinical or clinical trials for cancers, but the molecular basis of sensitivity or resistance to these inhibitors among patients is largely unknown. Here we have identified oncogenic variants of phosphoinositide-3-kinase, catalytic, α polypeptide (PIK3CA) and KRAS as determinants of response to the mTOR inhibitor everolimus. Human cancer cells carrying alterations in the PI3K pathway were responsive to everolimus, both in vitro and in vivo, except when KRAS mutations occurred concomitantly or were exogenously introduced. In human cancer cells with mutations in both PIK3CA and KRAS, genetic ablation of mutant KRAS reinstated response to the drug. Consistent with these data, PIK3CA mutant cells, but not KRAS mutant cells, displayed everolimus-sensitive translation. Importantly, in a cohort of metastatic cancer patients, the presence of oncogenic KRAS mutations was associated with lack of benefit after everolimus therapy. Thus, our results demonstrate that alterations in the KRAS and PIK3CA genes may represent biomarkers to optimize treatment of patients with mTOR inhibitors.
AB - Personalized cancer medicine is based on the concept that targeted therapies are effective on subsets of patients whose tumors carry specific molecular alterations. Several mammalian target of rapamycin (mTOR) inhibitors are in preclinical or clinical trials for cancers, but the molecular basis of sensitivity or resistance to these inhibitors among patients is largely unknown. Here we have identified oncogenic variants of phosphoinositide-3-kinase, catalytic, α polypeptide (PIK3CA) and KRAS as determinants of response to the mTOR inhibitor everolimus. Human cancer cells carrying alterations in the PI3K pathway were responsive to everolimus, both in vitro and in vivo, except when KRAS mutations occurred concomitantly or were exogenously introduced. In human cancer cells with mutations in both PIK3CA and KRAS, genetic ablation of mutant KRAS reinstated response to the drug. Consistent with these data, PIK3CA mutant cells, but not KRAS mutant cells, displayed everolimus-sensitive translation. Importantly, in a cohort of metastatic cancer patients, the presence of oncogenic KRAS mutations was associated with lack of benefit after everolimus therapy. Thus, our results demonstrate that alterations in the KRAS and PIK3CA genes may represent biomarkers to optimize treatment of patients with mTOR inhibitors.
UR - http://www.scopus.com/inward/record.url?scp=77955288855&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955288855&partnerID=8YFLogxK
U2 - 10.1172/JCI37539
DO - 10.1172/JCI37539
M3 - Article
C2 - 20664172
AN - SCOPUS:77955288855
SN - 0021-9738
VL - 120
SP - 2858
EP - 2866
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 8
ER -